Analysts Issue Forecasts for Omeros Co.’s FY2023 Earnings (NASDAQ:OMER)

Omeros Co. (NASDAQ:OMERGet Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings estimates for Omeros in a research note issued to investors on Wednesday, March 15th. Cantor Fitzgerald analyst B. Folkes expects that the biopharmaceutical company will earn ($2.61) per share for the year. The consensus estimate for Omeros’ current full-year earnings is ($2.31) per share.

Several other research analysts have also recently weighed in on OMER. started coverage on shares of Omeros in a research report on Thursday. They issued a “sell” rating on the stock. UBS Group cut shares of Omeros from a “buy” rating to a “neutral” rating in a research report on Thursday, December 8th.

Omeros Stock Down 9.9 %

OMER stock opened at $3.54 on Friday. The company has a current ratio of 3.25, a quick ratio of 7.30 and a debt-to-equity ratio of 2.58. The company’s 50 day moving average is $3.61 and its 200 day moving average is $3.28. The stock has a market cap of $222.42 million, a price-to-earnings ratio of 4.72 and a beta of 1.02. Omeros has a 1-year low of $1.74 and a 1-year high of $7.75.

Institutional Trading of Omeros

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ronald Blue Trust Inc. purchased a new stake in shares of Omeros during the second quarter valued at approximately $30,000. Lesa Sroufe & Co bought a new position in shares of Omeros during the third quarter valued at $56,000. Coldstream Capital Management Inc. bought a new position in shares of Omeros during the fourth quarter valued at $40,000. Laurion Capital Management LP bought a new stake in Omeros in the 2nd quarter worth about $49,000. Finally, MetLife Investment Management LLC increased its holdings in Omeros by 139.3% in the 1st quarter. MetLife Investment Management LLC now owns 28,967 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 16,862 shares in the last quarter. Hedge funds and other institutional investors own 32.64% of the company’s stock.

Omeros Company Profile

(Get Rating)

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

See Also

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.